TIBET RHODIOLA PHARMACEUTICAL HOLDING CO.

Autres langues Tibet Rhodiola Pharmaceutical Holding Co.

Actions

600211

CNE000000ZW7

Produits pharmaceutiques

Cours en clôture Shanghai S.E. Autres places de cotation 05/08/2026			Varia. 5j.	Varia. 1 janv.
38,60 ^CNY	-1,28%		+1,13%	-9,28%

08/05	Tibet Rhodiola Pharmaceutical Holding : le conseil d'administration élit son président	RE
28/04	Tibet Rhodiola Pharmaceutical Holding Co. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI

Autres langues

01/07	Tranche Update on Tibet Rhodiola Pharmaceutical Holding Co.'s Equity Buyback Plan announced on December 18, 2025.
08/05	Tibet Rhodiola Pharmaceutical Holding's board elects chairman
28/04	Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the First Quarter Ended March 31, 2026
01/04	Tranche Update on Tibet Rhodiola Pharmaceutical Holding Co.'s Equity Buyback Plan announced on December 18, 2025.
13/03	Tibet Rhodiola Pharmaceutical Logs 11% Decline in 2025 Profit, Revenue Up 6%
12/03	Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Full Year Ended December 31, 2025
05/01	Tranche Update on Tibet Rhodiola Pharmaceutical Holding Co.'s Equity Buyback Plan announced on December 18, 2025.
18/12	Tibet Rhodiola Pharmaceutical Holding Co. announces an Equity Buyback.
18/12	Tibet Rhodiola Pharmaceutical Holding Co. authorizes a Buyback Plan.
30/10/25	Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Nine Months Ended September 30, 2025
30/09/25	Ruizheng Gene Co., Ltd. announced that it has received $75 million in funding from China Medical System Holdings Limited, Tibet Rhodiola Pharmaceutical Holding Co.
27/08/25	Accuredit Therapeutics Us Limited announced that it expects to receive $75 million in funding from TopRidge Pharma Limited, Cms Medical Venture Investment (HK) Limited, Tibet Rhodiola Pharmaceutical Holding Co., Shenzhen Kangzhe Pharmaceutical Co., Ltd.
27/08/25	Accuredit announced that it has received $75 million in funding from Tibet Rhodiola Pharmaceutical Holding Co., Shenzhen Kangzhe Pharmaceutical Co., Ltd.
15/08/25	Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Half Year Ended June 30, 2025
19/05/25	Rhodiola Pharmaceutical Gets Nod to Build New Production Line for Heart Drug
28/04/25	Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the First Quarter Ended March 31, 2025
14/03/25	Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Full Year Ended December 31, 2024
25/10/24	Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Nine Months Ended September 30, 2024
15/10/24	Tibet Rhodiola Pharma's Unit Gets Nod to Amend Heart Drug's Registration Standards
13/08/24	Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Half Year Ended June 30, 2024
26/04/24	Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the First Quarter Ended March 31, 2024
26/03/24	Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Full Year Ended December 31, 2023
14/01/24	Chengdu Nuo´en Genomics Co., Ltd. announced that it has received funding from Jiaxing Anhong Zhifei Venture Capital Partnership (Limited Partnership), Tibet Rhodiola Pharmaceutical Holding Co.
26/10/23	Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Nine Months Ended September 30, 2023
24/08/23	Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Half Year Ended June 30, 2023